

STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage: Protocol for a randomised controlled trial

European Stroke Journal
2020, Vol. 5(4) 414–422
© European Stroke Organisation 2020



Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2396987320954671
journals.sagepub.com/home/eso



Kristin Tveitan Larsen^{1,2} , Elisabeth Forfang²,
Johanna Pennlert³, Eva-Lotta Glader³, Christina Kruuse⁴,
Per Wester^{3,5}, Hege Ihle-Hansen^{2,6}, Maria Carlsson^{7,8},
Eivind Berge¹, Rustam Al-Shahi Salman⁹,
Torgeir Bruun Wyller^{1,2} and Ole Morten Rønning^{2,10} 

Abstract

Background and aims: Many patients with prior intracerebral haemorrhage have indications for antithrombotic treatment with antiplatelet or anticoagulant drugs for prevention of ischaemic events, but it is uncertain whether such treatment is beneficial after intracerebral haemorrhage. STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage will assess (i) the effects of long-term antithrombotic treatment on the risk of recurrent intracerebral haemorrhage and occlusive vascular events after intracerebral haemorrhage and (ii) whether imaging findings, like cerebral microbleeds, modify these effects.

Methods: STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage is a multicentre, randomised controlled, open trial of starting versus avoiding antithrombotic treatment after non-traumatic intracerebral haemorrhage, in patients with an indication for antithrombotic treatment. Participants with vascular disease as an indication for antiplatelet treatment are randomly allocated to antiplatelet treatment or no antithrombotic treatment. Participants with atrial fibrillation as an indication for anticoagulant treatment are randomly allocated to anticoagulant treatment or no anticoagulant treatment. Cerebral CT or MRI is performed before randomisation. Duration of follow-up is at least two years. The primary outcome is recurrent intracerebral haemorrhage. Secondary outcomes include occlusive vascular events and death. Assessment of clinical outcomes is performed blinded to treatment allocation. Target recruitment is 500 participants.

Trial status: Recruitment to STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage is on-going. On 30 April 2020, 44 participants had been enrolled in 31 participating hospitals. An individual patient–data meta-analysis is planned with similar randomised trials.

Keywords

Intracerebral haemorrhage, antithrombotic treatment, secondary prevention, ischaemic events, randomised controlled trial, antiplatelet, anticoagulant, atrial fibrillation, stroke

Date received: 13 May 2020; accepted: 29 July 2020

¹Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway

²University of Oslo, Institute of Clinical Medicine, Oslo, Norway

³Department of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden

⁴Herlev Gentofte Hospital and University of Copenhagen, Herlev, Denmark

⁵Department of Clinical Sciences, Karolinska Institute, Danderyds Hospital, Stockholm, Sweden

⁶Department of Neurology, Oslo University Hospital, Oslo, Norway

⁷Department of Neurology, Nordland Hospital Trust, Bodø, Norway

⁸Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway

⁹Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

¹⁰Department of Neurology, Akershus University Hospital, Lørenskog, Norway

Corresponding author:

Kristin Tveitan Larsen, Oslo universitetssykehus, Ullevål Building 20, 4th floor P.O. Box 4950, Oslo 0407 Norway.

Email: k.t.larsen@medisin.uio.no

Background and aims

Antithrombotic treatment is well-established for patients without prior intracerebral haemorrhage (ICH): antiplatelet drugs for the prevention of serious vascular events in patients with vascular disease^{1,2} and anticoagulant drugs to prevent systemic embolism in patients with atrial fibrillation,^{3,4} among other indications. However, antithrombotic drugs increase the risk of bleeding and ICH is the most severe and feared complication. Forty percent of patients suffering from ICH die within the first month and more than half the survivors become dependent on help from others.⁵

The annual risk of ICH recurrence is estimated to be 1.8–7.4%,⁶ but in the long term, these patients are at even higher risk of ischaemic events like myocardial infarction and ischaemic stroke.^{7,8} A substantial proportion of patients presenting with ICH are on antithrombotic treatment: a quarter use anticoagulant drugs,^{9,10} and more than one-third use antiplatelet drugs.^{11,12} Overall, 40–50% use, or have an indication for, antithrombotic treatment.^{8,13} After the acute phase of the ICH, the physician must decide whether to resume the antithrombotic drug or not. However, preventing a possibly devastating ischaemic event with a drug that might cause a new ICH creates a clinical dilemma because the safety of antithrombotic drugs is unknown in patients with prior ICH. Guidelines do not make clear recommendations about this,^{14–16} both policies occur in standard clinical practice,^{17–19} and clinical equipoise is demonstrated in surveys in the UK and Scandinavia.²⁰

Until recently, no randomised controlled trials have assessed effects of long-term antithrombotic treatment after ICH.²¹ Observational studies have investigated the safety of antiplatelet^{18,22–28} and anticoagulant^{8,29–38} treatment after different types of intracranial haemorrhage including ICH. Overall, in these studies, antithrombotic drugs were not associated with an increased risk of recurrent ICH. However, associations with the risk of ischaemic events varied, most of the studies were small, and they were prone to selection bias and confounding by indication.

Recently, the RESTART randomised controlled trial of 537 patients investigated effects of antiplatelet treatment after ICH.³⁹ During a median follow-up period of two years, RESTART did not show an increase in the rate of recurrent ICH from antiplatelet drugs, but on the contrary a non-significant reduction in the risk of recurrent ICH (adjusted hazard ratio 0.51, 95% CI 0.25–1.03; $p = 0.060$). The RESTART results are reassuring for antiplatelet treatment but need to be confirmed by other randomised trials.

The recently presented NASPAF-ICH trial (Non-Vitamin K Antagonist Oral Anticoagulants for

Stroke Prevention in Patients With Atrial Fibrillation and Previous Intracerebral Hemorrhage Study) randomised 30 participants with atrial fibrillation and previous ICH to Non-Vitamin K antagonist oral anticoagulants versus Aspirin.⁴⁰ The primary feasibility outcome was recruitment rate, which was 3.1 participants/site/year. During a mean follow-up period of 1.53 years, no recurrent ICH occurred. However, this was a phase II feasibility trial, too small to draw conclusions about clinical outcome data. More evidence is needed to guide both anticoagulant and antiplatelet treatment after ICH.

It is also uncertain whether one should give or avoid antithrombotic treatment in ICH patients with many cerebral microbleeds or cerebral amyloid angiopathy (CAA), who at the same time have a high risk of ischaemic events. Cerebral microbleeds are associated with increased risk of ICH,^{41–43} but also with increased risk of ischaemic stroke.^{41,44} Lobar microbleeds might indicate CAA, which is also associated with a higher ICH recurrence rate.⁴⁵ However, in a cohort study of 1012 patients with atrial fibrillation and prior ICH, even those who fulfilled criteria for possible or probable CAA showed an association between resuming anticoagulation and better outcome on mortality and functional status.³⁶ The interaction between these imaging findings and the effects of antithrombotic treatment is still unknown.

The primary aim of Study of Antithrombotic Treatment after IntraCerebral Haemorrhage (STATICH) is to assess the effects of antithrombotic drugs on the risk of recurrent ICH and occlusive vascular events after ICH. The secondary aim is to assess whether brain imaging findings, like cerebral microbleeds, modify the effects of antithrombotic treatment after ICH.

Methods

Trial design and overview

STATICH is a Scandinavian, investigator-led, multi-centre, randomised controlled, open trial of antithrombotic treatment for prevention of ischaemic disease in patients with prior ICH. The trial is conducted according to Good Clinical Practice and The Declaration of Helsinki. Regulatory agencies and ethics committees in the three participating countries have approved the trial. The EudraCT number is 2014-002636-13 and the ClinicalTrials.gov number is NCT03186729.

Patient population and consent

Participants are recruited during hospital admission or in an outpatient clinic. Patients are eligible for the trial

Table 1. Eligibility criteria.

Inclusion criteria

- Patient age ≥ 18 years
- Non-traumatic, primary intracerebral haemorrhage ≥ 24 hours ago, and:
 - No preceding traumatic brain injury, based on history from the patient/witness of spontaneous symptom onset, and brain imaging appearances consistent of spontaneous intracerebral haemorrhage (i.e. any brain/bone/soft tissue appearances of trauma must have occurred secondary to a spontaneous intracerebral haemorrhage)
 - No underlying structural cause (e.g. aneurysm, tumour, arteriovenous malformation, intracerebral venous thrombosis, or haemorrhagic transformation of an ischaemic stroke)
- Patient has indication for antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of ischaemic events, either antiplatelet drugs for patients with vascular disease, or anticoagulant drug for patients with atrial fibrillation. Indication for antiplatelet drugs can be previous ischaemic stroke, myocardial infarction, other occlusive arterial disease, or arterial stents or other arterial implants (secondary prevention), or patients with known significant atherosclerotic arterial disease, such as carotid or coronary artery stenosis or mobile aortic atheroma (primary prevention)
- Consent to randomisation from the patient (or personal/legal/professional representative, if the patient does not have mental capacity to give consent, and waiver of consent is acceptable in the patient's country)
- CT and/or MRI is performed before randomisation

Exclusion criteria

- Clear indication for antiplatelet or anticoagulant treatment (e.g. recent coronary artery stenting, or prosthetic metallic heart valves)
- Contraindications to the antithrombotic drug that will be administered
- Patient is pregnant, breastfeeding or of childbearing potential and not using contraception. A woman of childbearing potential must undergo a pregnancy test before randomisation and the result must be recorded in the case report form. Women of childbearing potential randomised to active treatment must use effective methods of contraception and undergo regular pregnancy testing during follow-up, and the results must be recorded in the case report forms.
- For MRI examination: Contraindication to the brain MRI
- Malignancy with life expectancy less than two years

if they are 18 years old or more, have had a prior non-traumatic ICH minimum one day ago and have an indication for antithrombotic treatment for prevention of ischaemic events. There must be no preceding traumatic brain injury or underlying structural cause of the ICH, defined as tumour, aneurysm, vascular malformation, intracerebral venous thrombosis or haemorrhagic transformation of an ischaemic stroke. There must be no compelling indication for antithrombotic treatment (e.g. recent coronary artery stenting or prosthetic metallic heart valve). Detailed eligibility criteria are shown in Table 1.

Written informed consent is obtained from the participant by the treating physician before enrolment. If the participant lacks capacity to consent, consent is obtained from the participant's legal representative, if this is accepted in the respective country. If such a participant regains capacity to consent a later stage, written informed consent is then obtained from the participant.

Imaging

All participants have cerebral MRI or CT scans performed in relation to the qualifying ICH, but before

randomisation, if there are no contraindications. For the MRI scan, susceptibility-weighted imaging sequence(s), T1, T2 and FLAIR images in a 3 T MRI scanner are preferred, but a standard MRI stroke protocol in a 1.5 T MRI scanner is acceptable. All cerebral CT and MRI scans performed after the qualifying event and before the time of randomisation are sent on CD ROM to the Trial Co-ordinating Centre in DICOM viewer format. In selected hospitals, participants will undergo a new cerebral MRI scan after two years, to enable assessment of how antithrombotic treatment affects the development of different imaging findings. Two radiologists, blinded to treatment allocation, will independently interpret the CT and MRI scans according to pre-specified criteria.

Randomisation and intervention

The intervention is treatment with an antithrombotic drug. The control is a policy of avoiding these drugs. Participants with vascular disease and indication for antiplatelet treatment are randomised to starting antiplatelet treatment or avoiding antithrombotic treatment altogether. Participants with atrial fibrillation and an indication for anticoagulant treatment are




Figure 1. STATICH flowchart.

randomised to starting anticoagulant treatment or avoiding anticoagulant treatment (which may include antiplatelet drugs or left atrial appendage occlusion; Figure 1, flowchart).

Randomisation is performed by a web-based, central randomisation system that allocates the participants to intervention or control, according to a minimisation algorithm without a pre-determined sequence. The algorithm prevents predictable alternation of allocation by randomly allocating the first participant with a probability of 0.5 to one of the arms. Adaptive stratification is used to allocate each subsequent participant with a probability of 0.8 to the arm that minimises the difference between the arms, with respect to baseline characteristics in the previously randomised participants. Treatment allocation for an individual participant is revealed only after the baseline data are submitted, and is open to participants, treating physicians and local research staff, as well as personnel in the Trial Co-ordinating Centre assessing protocol adherence. The dedicated personnel recording clinical outcome events are blinded to treatment allocation.

The central Event Adjudication Committee that evaluates all outcome events is also blinded to treatment allocation.

The timing of randomisation after the qualifying ICH is up to the treating physician. If the participant is allocated to an antithrombotic drug, the drug should be initiated within 24 h after randomisation. For participants allocated to treatment, the treating physician is responsible for choosing the type and dose of the antithrombotic drug, in accordance with standard clinical practice.

Follow-up

Participants receive a patient card containing the study code, the name of the Sponsor and the telephone number to the Trial Co-ordinating Centre. When a participant is included, and thereafter at six months' intervals, the national Co-ordinating Centre sends a letter to the participant and the general practitioner to remind them of the treatment allocation. The participant is contacted by the national Co-ordinating Centre at

one month and every six months for at least two years after randomisation by telephone. The focus is the participant's safety, any adverse events and adherence to the protocol. Recording of adherence and outcomes is done by structured interviews with the participant, his/her nearest relative and/or the general practitioner, and by collecting data from medical records. If a participant develops any exclusion criteria, withdrawal from the allocated treatment may be considered. The follow-up schedule continues for all randomised participants, unless they choose to withdraw from follow-up. The pre-determined duration of follow-up for the primary/secondary outcomes is two years.

Follow-up at 5 and 10 years will occur by telephone interviews with participants, collection of data from medical records and linkage with participants' data in national registers, to determine long-term survival and risk of vascular events.

Co-enrolment into other trials during follow-up is allowed by the chief investigator, if no interaction between trial interventions can be expected, and co-enrolment does not interfere with follow-up in STATICH.

Assessment of outcome events

The primary outcome is occurrence of new, symptomatic ICH over at least two years of follow-up. Secondary outcomes are other intracranial haemorrhagic events, major and minor extracranial haemorrhagic events, occlusive vascular events (transient ischaemic attack, ischaemic stroke, unstable angina, acute myocardial infarction, peripheral arterial occlusion, mesenteric ischaemia, central retinal arterial occlusion, revascularisation procedures (carotid, coronary, peripheral arterial), symptomatic deep vein thrombosis and symptomatic pulmonary embolism), vascular death, all-cause death and functional status according to the modified Rankin Scale (Table 2). Data collection forms used in the trial are available from the corresponding author upon request.

Subgroup analyses

Relevant subgroups are those defined by age, type of antithrombotic drug, timing of treatment initiation and haemorrhage location. For participants randomised to anticoagulants versus control, relevant subgroups also include CHA₂DS₂VASc score⁴⁶ and HAS-BLED score.⁴⁷ Pre-specified subgroup analyses will also examine possible interactions between imaging findings, like cerebral microbleeds, and effects of antithrombotic treatment on the risk of recurrent ICH.

Statistical considerations

The risk of ICH recurrence is estimated to be 1.8–7.4% per year.⁶ There is uncertainty about the relative increase in the risk of recurrent ICH on antiplatelet or anticoagulant drugs, but observational studies indicate no increased risk of recurrent haemorrhage compared to not taking antithrombotic drugs.^{8,18,22–38} A fourfold increase in the risk of recurrent ICH on antithrombotic drugs (from about 2% to 8%) would be considered unacceptable and higher than any plausible effect antithrombotic drugs would have on ischaemic events. With 500 participants randomised to antiplatelets versus control, or to anticoagulants versus control, STATICH will have more than 80% power at the 5% significance level to detect such a difference. STATICH aims to randomise 500 participants to antiplatelets versus control, and more than 50 participants to anticoagulants versus control. Information from the latter will be used to assess the plausibility of a net benefit in a larger main study. These sample size calculations were made before results from the RESTART trial were reported and are therefore based on prior assumptions. The target sample size and inclusion period will be reviewed and adjusted by the Trial Steering Committee based on overall data (not by treatment group) on primary outcome events, the number of participants in pre-specified subgroups and completeness of follow-up.

The primary analysis will be restricted to the primary outcome and performed separately for the antiplatelet and anticoagulant part of the trial. Subgroup analyses will be performed for the primary outcome and interactions will be tested, if appropriate. Secondary analyses will be performed for the secondary outcomes. All participants will be included in the analyses. To retain the benefit of randomisation, all participants will be analysed according to the 'intention to treat' principle, i.e. in the group to which they were allocated, irrespective of whether they adhere to the allocated treatment. We intend to publish a separate statistical analysis plan before the follow-up is complete and the data base is locked.

Safety

STATICH is a pragmatic trial, investigating which of two forms of standard clinical care is most beneficial. The drugs are well-known and used for standard indications. Data on outcomes and serious adverse events are routinely collected and evaluated. Procedures for management of adverse drug reactions are specified in the standard operating procedures. In case of an unexpected serious adverse event (SUSAR), the Trial Coordinating Centre should be notified immediately.

Table 2. Outcome events.

Primary outcome
Fatal or non-fatal symptomatic intracerebral haemorrhage (neurological deterioration or death associated with intracerebral haemorrhage found on CT scan, MRI scan, or by autopsy) over at least two years of follow-up
Secondary outcomes
<ul style="list-style-type: none"> • Occlusive vascular events: transient ischaemic attack (requiring hospitalisation), ischaemic stroke, unstable angina (requiring revascularisation), acute myocardial infarction, peripheral arterial occlusion, mesenteric ischaemia, central retinal arterial occlusion, revascularisation procedures (carotid, coronary, peripheral arterial) symptomatic deep vein thrombosis or symptomatic pulmonary embolism • Symptomatic (spontaneous or traumatic) epidural, subdural or subarachnoid haemorrhage • Major extracranial bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH-criteria⁵⁰): <ol style="list-style-type: none"> 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial or intramuscular with compartment syndrome, and/or 3. Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. • Clinically relevant non-major bleeding (ISTH-criteria⁵¹): <ol style="list-style-type: none"> 1. Requiring medical intervention by a healthcare professional, or 2. Leading to hospitalisation or increased level of care, or 3. Prompting a face to face (i.e. not just a telephone or electronic communication) evaluation • Vascular death • Death from any cause • Functional status (according to the modified Rankin Scale) at two years

Sponsor will report the SUSAR in an expedited manner to the authorities according to the applicable regulatory requirements. The Data Monitoring Committee will perform un-blinded reviews of outcome events in all participants and in the pre-specified subgroups during the trial. The committee will also perform an un-blinded interim analysis of the primary outcome variable when half the participants have been included.

Data quality

The trial will be monitored according to the risk assessment. Monitoring will be independent from investigators and Sponsor. The central randomisation system checks eligibility for all participants. To facilitate protocol adherence and fulfilling of the trial's objectives, there will be frequent telephone contacts between the Trial Co-ordinating Centre and participating hospitals.

Study organisation

Oslo University Hospital is the Sponsor. The Director of Research acts as the Sponsor's legal representative. The Trial Co-ordinating Centre is hosted within the Stroke Research Group at Oslo University Hospital (Ullevål). The Trial Co-ordinating Centre works in close collaboration with the Trial Imaging Centre at Akershus University Hospital, and with National Co-ordinating Centres in Sweden and Denmark. The

STATICH Study Group comprises all hospitals participating in the trial. A list of all participating hospitals is available from the corresponding author on request.

Publication policy

The primary results of the trial will be published in international peer reviewed journals, presented at international scientific meetings, and communicated as popular science articles in public media.

Current trial status

The current protocol version is dated 05 March 2020. Important protocol modifications are communicated to relevant parties during the trial. Recruitment started in June 2018 and is on-going. On 30 April 2020, a total of 44 participants had been randomised in 31 participating hospitals: 21 to antiplatelets versus control, and 23 to anticoagulants versus control.

Discussion

Randomised controlled trials assessing effects of long-term antithrombotic treatment after ICH are needed for several reasons. First, it is likely that antithrombotic treatment prevents ischaemic events even after ICH, but these patients were not included in previous randomised trials of antithrombotic treatment, and the effect of these drugs on the risk of recurrent ICH is

uncertain. Second, although observational studies have not shown an association between antithrombotic treatment and increased risk of recurrent ICH,^{8,18,22–38} observational studies are insufficient to guide this treatment decision. Third, guidelines vary, and there is evidence of clinical equipoise about the use of antithrombotic treatment after ICH in clinical practice. Recruitment to STATICH might be hampered by the physician's assessment of patient frailty and short life expectancy after ICH. However, many of the long-term survivors after ICH live functionally independent lives⁴⁸ and need optimised prevention of vascular disease.

The recently published RESTART randomised trial showed that restarting antiplatelet treatment at a median of 76 days after ICH might halve the risk of recurrent ICH.³⁹ These results were opposite to prior expectations and their reproducibility should be investigated in other randomised trials. Furthermore, RESTART did not identify any harmful effects from antiplatelet treatment in the subgroups with lobar haemorrhage or cerebral microbleeds of different patterns.⁴⁹ The subgroups were small and more data are needed, but the results permit inclusion of patients with a variety of imaging findings into other randomised trials.

In addition to RESTART and STATICH, only one other trial is currently assessing effects of antiplatelet treatment after ICH (RESTART France, NCT02966119), to our knowledge. Anticoagulant treatment after ICH is being investigated by several other on-going trials: APACHE-AF (NCT02565693), SOSTART (NCT03153150), A3ICH (NCT03243175), ENRICH-AF (NCT03950076), ASPIRE (NCT03907046) and PRESTIGE-AF (NCT03996772), in addition to the completed NASPAF-ICH feasibility trial. Data from – hopefully – all these trials will be combined with results from STATICH in a prospectively planned, individual patient–data meta-analysis. This meta-analysis aims to provide statistical power to evaluate both the overall effects of antithrombotic treatment after ICH, as well as the effects in subgroups of patients, e.g. by ICH location and other brain imaging findings.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JP has served on a scientific advisory board for and received lecture fees from Bayer. CK has received lecture fees from Novo Nordic and Bristol-Myers Squibb Denmark. The other authors declare that they have no competing interests.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: STATICH has received funding from Oslo University Hospital, Umeå University, Västerbottens Läns Landsting, Simon Fougner Hartmanns Familiefond, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal, and Novo Nordic Foundation (grant NNF18OK0031840). The funding sources have no role in the trial design, data collection, analysis or interpretation of the data, writing of the manuscript or presentation of the results.

Ethical approval

Ethics committees in the three participating countries have approved the trial.

Informed consent

Written informed consent is obtained from the participants or from their legally authorised representatives (if waiver of consent is acceptable in the participant's country) before inclusion in the trial.

Guarantor

OMR.

Trial registration

The EudraCT number is 2014-002636-13 and the ClinicalTrials.gov number is NCT03186729.

Contributorship


EB, OMR, RA-SS and EF conceived and designed the trial. EB, OMR and EF wrote the first version of the study protocol. All authors contributed to further protocol development. EB and EF contacted national co-ordinating investigators. EB, OMR, EF, JP, ELG and CK gained approvals from authorities. EB, EF, OMR, KTL, JP, ELG and CK obtained funding. EB, RA-SS, EF and KTL contributed to the development of the randomisation system. EB, KTL, JP, ELG and CK initiated participating hospitals. EB, KTL, JP, ELG, CK, PW, HIH, MC and OMR contributed to participant recruitment. KTL drafted the first version of the manuscript. All authors (except EB) critically reviewed and approved the final version.

Acknowledgements

We would like to thank all participating hospitals and local investigators for contributing to STATICH. We would also like to thank Edinburgh Clinical Trials Unit for development of the randomisation system. STATICH was initiated by our dear friend and colleague, Professor Eivind Berge, who sadly died on 6 February 2020.

ORCID iDs

Kristin Tveitan Larsen  <https://orcid.org/0000-0002-1310-8243>

Ole Morten Rønning  <https://orcid.org/0000-0001-5080-5788>

References

1. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002; 324: 71–86.
2. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009; 373: 1849–1860.
3. Hart RG, Pearce LA and Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007; 146: 857–867.
4. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; 383: 955–962.
5. van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol* 2010; 9: 167–176.
6. Poon MT, Fonville AF and Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. *J Neurol Neurosurg Psychiatr* 2014; 85: 660–667.
7. Casolla B, Moulin S, Kyheng M, et al. Five-year risk of major ischemic and hemorrhagic events after intracerebral hemorrhage. *Stroke* 2019; 50: 1100–1107.
8. Ottosen TP, Grijota M, Hansen ML, et al. Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. *Stroke* 2016; 47: 1837–1843.
9. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. *Neurology* 2007; 68: 116–121.
10. Schols AM, Schreuder FH, van Raak EP, et al. Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands. *Stroke* 2014; 45: 268–270.
11. Khan NI, Siddiqui FM, Goldstein JN, et al. Association between previous use of antiplatelet therapy and intracerebral hemorrhage outcomes. *Stroke* 2017; 48: 1810–1817.
12. Bejot Y, Cordonnier C, Durier J, et al. Intracerebral hemorrhage profiles are changing: results from the Dijon population-based study. *Brain* 2013; 136: 658–664.
13. Lovelock CE, Molyneux AJ and Rothwell PM. Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. *Lancet Neurol* 2007; 6: 487–493.
14. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. *Int J Stroke* 2014; 9: 840–855.
15. Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2015; 46: 2032–2060.
16. Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. *Eur Stroke J* 2019; 4: 198–223.
17. Pasquini M, Charidimou A, van Asch CJ, et al. Variation in restarting antithrombotic drugs at hospital discharge after intracerebral hemorrhage. *Stroke* 2014; 45: 2643–2648.
18. Viswanathan A, Rakich SM, Engel C, et al. Antiplatelet use after intracerebral hemorrhage. *Neurology* 2006; 66: 206–209.
19. Pennlert J, Asplund K, Carlberg B, et al. Antithrombotic treatment following intracerebral hemorrhage in patients with and without atrial fibrillation. *Stroke* 2015; 46: 2094–2099.
20. Forfang E, Bell S, Berge E, et al. Oral anticoagulation after intracranial haemorrhage: results of surveys among stroke physicians (Poster Abstract). *Eur Stroke J* 2016; 1: 3–612.
21. Perry LA, Berge E, Bowditch J, et al. Antithrombotic treatment after stroke due to intracerebral haemorrhage. *Cochrane Database Syst Rev* 2017; 5: Cd012144.
22. Biffi A, Halpin A, Towfighi A, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. *Neurology* 2010; 75: 693–698.
23. Chong BH, Chan KH, Pong V, et al. Use of aspirin in Chinese after recovery from primary intracranial haemorrhage. *Thromb Haemost* 2012; 107: 241–247.
24. Flynn RW, MacDonald TM, Murray GD, et al. Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage. *Stroke* 2010; 41: 2606–2611.
25. Teo KC, Lau GKK, Mak RHY, et al. Antiplatelet resumption after antiplatelet-related intracerebral hemorrhage: a retrospective hospital-based study. *World Neurosurg* 2017; 106: 85–91.
26. Ding X, Liu X, Tan C, et al. Resumption of antiplatelet therapy in patients with primary intracranial hemorrhage-benefits and risks: a meta-analysis of cohort studies. *J Neurol Sci* 2018; 384: 133–138.
27. Gonzalez-Perez A, Gaist D, de Abajo FJ, et al. Low-dose aspirin after an episode of haemorrhagic stroke is associated with improved survival. *Thromb Haemost* 2017; 117: 2396–2405.
28. Chen CJ, Ding D, Buell TJ, et al. Restarting antiplatelet therapy after spontaneous intracerebral hemorrhage: functional outcomes. *Neurology* 2018; 91: e26–e36.
29. Majeed A, Kim YK, Roberts RS, et al. Optimal timing of resumption of warfarin after intracranial hemorrhage. *Stroke* 2010; 41: 2860–2866.

30. Claassen DO, Kazemi N, Zubkov AY, et al. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. *Arch Neurol* 2008; 65: 1313–1318.
31. Yung D, Kapral MK, Asllani E, et al. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. *Can J Cardiol* 2012; 28: 33–39.
32. Nielsen PB, Larsen TB, Skjoth F, et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. *Circulation* 2015; 132: 517–525.
33. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. *JAMA* 2015; 313: 824–836.
34. Chao TF, Liu CJ, Liao JN, et al. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. *Circulation* 2016; 133: 1540–1547.
35. Poli D, Antonucci E, Dentali F, et al. Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. *Neurology* 2014; 82: 1020–1026.
36. Biffi A, Kuramatsu JB, Leasure A, et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage. *Ann Neurol* 2017; 82: 755–765.
37. Murthy SB, Gupta A, Merkler AE, et al. Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. *Stroke* 2017; 48: 1594–1600.
38. Korompoki E, Filippidis FT, Nielsen PB, et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. *Neurology* 2017; 89: 687–696.
39. Al-Shahi Salman R, Dennis MS, Sandercock PAG, et al. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. *Lancet* 2019; 393: 2613–2623.
40. Shoamanesh A, Sharma M, Dowlathshahi D, et al. Non-vitamin K oral anticoagulants in intracerebral hemorrhage survivors with atrial fibrillation: primary results of the NASPAF-ICH randomized trial, Conference abstract, <https://www.abstractsonline.com/pp8/#!/7927/presentation/5388> (2020, 07 May 2020).
41. Akoudad S, Portegies ML, Koudstaal PJ, et al. Cerebral microbleeds are associated with an increased risk of stroke: the Rotterdam study. *Circulation* 2015; 132: 509–516.
42. Charidimou A, Shakeshaft C and Werring DJ. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. *Front Neurol* 2012; 3: 133.
43. Greenberg SM, Eng JA, Ning M, et al. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. *Stroke* 2004; 35: 1415–1420.
44. Wilson D, Ambler G, Lee KJ, et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. *Lancet Neurol* 2019; 18: 653–665.
45. Charidimou A, Imaizumi T, Moulin S, et al. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis. *Neurology* 2017; 89: 820–829.
46. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010; 137: 263–272.
47. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010; 138: 1093–1100.
48. Tveiten A, Ljostad U, Mygland A, et al. Functioning of long-term survivors of first-ever intracerebral hemorrhage. *Acta Neurol Scand* 2014; 129: 269–275.
49. Al-Shahi Salman R, Minks DP, Mitra D, et al. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. *Lancet Neurol* 2019; 18: 643–652.
50. Schulman S and Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005; 3: 692–694.
51. Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost* 2015; 13: 2119–2126.